Skip to main content
. Author manuscript; available in PMC: 2009 Nov 16.
Published in final edited form as: J Immunotoxicol. 2008 Jul;5(3):315–335. doi: 10.1080/15376510802312464

TABLE 5.

Potentially adenovector-related clinical pathology parameters by study

SERUM CHEMISTRIES Treated Controlsa
Parameter Study Product Timepoint Gender Direction Mean S.D.b Mean S.D.
Cholesterolc D 14 SD3 M ↑ 102 20.81 80 18.66
F ↑ 124 32.06 92 25.61
E 18 M ↑ 130.8 28.63 73.3 10.61
F ↑ 166.78 36.32 104.7 20.22
22 M ↑ 117.1 10.81 73.3 10.61
F ↑ 135.8 21.7 104.7 20.22
G 27 SD4 M ↓ 64 5.33 84.71 14.97
Triglyceridesd D 14 SD3 M ↑ 287 127.87 159 58.62
F ↑ 188 53.96 126 42.01
9, 14 SD86 M ↑ 744 570.96 192 178.16
E 18 SD3 M ↑ 404.9 198.73 153.9 48.28
F ↑ 318.78 222.7 138.6 54.81
22 M ↑ 297 107.63 153.9 48.28
F ↑ 216 30.61 138.6 54.81
G 27 SD4 M ↑ 187.5 72.8 126.8 44.59
SD30 M ↑ 145.6 66.18 82.9 22.2
Globuline D 14 SD3 M ↑ 2.3 0.15 2 0.12
F ↑ 2.2 0.1 2 0.1
SD24 M ↑ 2.2 0.13 2 0.08
F ↑ 2.2 0.12 1.9 0.1
SD36 M ↑ 2.2 0.23 1.9 0.14
9, 14 SD86 F ↑ 2.4 0.16 2.1 0.24
SD108 M ↑ 2.3 0.18 2.1 0.16
F ↑ 2.3 0.08 2.2 0.18
E 18 SD3 M ↑ 2.42 0.21 1.96 0.12
F ↑ 2.5 0.3 2.03 0.19
22 M ↑ 2.3 0.21 1.96 0.12
F ↑ 2.26 0.19 2.03 0.19
18 SD24 M ↑ 1.85 0.16 1.43 0.21
F ↑ 1.93 0.16 1.55 0.11
22 M ↑ 1.71 0.13 1.43 0.21
F ↑ 1.82 0.14 1.55 0.11
18 SD45 M ↑ 2.02 0.15 1.51 0.17
F ↑ 2.07 0.14 1.68 0.13
22 M ↑ 2.05 0.12 1.51 0.17
F ↑ 2.08 0.12 1.68 0.13
18 SD57 M ↑ 1.66 0.09 1.34 0.011
F ↑ 1.58 0.19 1.42 0.16
22 M ↑ 1.8 0.12 1.34 0.11
F 25, 21 SD90 M ↑ 2.43 0.16 2.07 0.14
F ↑ 2.59 0.13 2.2 0.22
SD120 F ↑ 2.28 0.15 2.08 0.11
G 27 SD4 M ↑ 2.26 0.11 2.1 0.14
SD30 M ↑ 2.22 0.08 2 0.08
F ↑ 2.32 0.27 2.05 0.1
SD45 M ↑ 2.16 0.15 1.96 0.09
F ↑ 2.2 0.07 2 0.16
SD57 F ↑ 2.38 0.19 2.08 0.08
A/G ratiof D 14 SD3 M ↓ 1.6 0.11 2 0.19
F ↓ 1.8 0.15 1.9 0.11
SD24 M ↓ 1.8 0.11 2 0.15
F ↓ 1.47 0.11 2 0.07
SD36 M ↓ 1.7 0.2 2 0.21
9, 14 SD86 F ↓ 1.7 0.18 2.1 0.16
E 18 SD3 M ↓ 1.53 0.13 1.88 0.16
F ↓ 1.47 0.16 1.83 0.22
22 M ↓ 1.66 0.18 1.88 0.16
F ↓ 1.59 0.18 1.83 0.22
18 SD24 M ↓ 2.17 0.22 2.95 0.56
F ↓ 2.06 0.24 2.61 0.17
22 M ↓ 2.4 0.24 2.95 0.56
F ↓ 2.18 0.22 2.61 0.17
18 SD45 M ↓ 1.97 0.18 2.77 0.37
F ↓ 1.95 0.19 2.33 0.18
22 M ↓ 2.05 0.16 2.77 0.37
F ↓ 1.87 0.16 2.33 0.18
18 SD57 M ↓ 2.42 0.21 2.99 0.2
F ↓ 2.23 0.09 2.77 0.23
22 F ↓ 2.45 0.16 2.77 0.23
F 25, 21 SD90 M ↓ 1.71 0.12 2.07 0.18
F ↓ 1.52 0.09 1.86 0.09
SD120 F ↓ 1.72 0.1 1.91 0.11
G 27 SD30 M ↓ 1.74 0.08 1.84 0.08
F ↓ 1.73 0.15 1.84 0.14
SD45 M ↓ 1.75 0.15 1.92 0.1
F ↓ 1.62 0.16 1.82 0.09
SD57 F ↓ 1.65 0.15 1.94 0.04
HEMATOLOGIES
Hemoglobing D 14 SD3 M ↓ 11.9 0.48 13.1 0.71
SD24 M ↓ 12 0.9 13.2 0.67
9,14 SD108 M ↓ 12.7 0.64 13.4 1.55
E 22 SD -4 M ↓ 12.53 0.75 13.3 0.54
18 SD3 M ↓ 11.54 0.66 12.35 0.81
22 M ↓ 10.92 0.75 12.35 0.81
F ↓ 11.16 0.5 12.07 0.58
18 SD24 M ↓ 12.96 0.66 13.92 0.5
22 M ↓ 12.91 0.64 13.92 0.5
18 SD45 M ↓ 14.18 0.56 14.75 0.59
22 M ↓ 13.94 0.56 14.75 0.59
F ↓ 13.84 0.37 14.41 0.65
F 25, 21 SD90 M ↓ 13.2 0.53 14.47 0.95
F ↓ 12.79 0.78 13.77 0.67
SD108 M ↓ 13.16 0.42 13.92 0.49
G 27 SD30 F ↓ 13.35 0.56 14.04 0.59
SD45 M ↓ 13.7 0.6 14.82 0.31
F ↓ 13.06 0.75 14.34 0.61
SD57 F ↑ 14.22 0.65 13.44 0.38
Hematocrith D 14 SD3 M ↓ 39.2 1.83 43.9 2.69
SD24 M ↓ 38.6 3.38 42.1 2.32
9, 14 SD120 M ↓ 44.1 1.28 47.1 1.46
E 18 SD -4 M ↓ 37.52 1.93 39.69 1.58
22 SD3 M ↓ 33.11 1.91 35.55 2.05
F ↓ 32.41 3.45 35.41 1.91
18 M ↓ 31.41 2.03 35.55 2.05
F ↓ 32.03 1.58 35.41 1.91
22 SD24 M ↓ 38.43 2.02 40.46 1.42
18 M ↓ 37.89 1.92 40.46 1.42
18 SD45 M ↓ 39.56 1.29 41.67 1.87
F 25, 21 SD -6 M ↑ 36.66 1.16 35.3 1.39
F ↓ 33.76 1.91 36.02 1.91
SD90 M ↓ 39.27 1.59 41.99 2.88
F ↓ 37.79 2.06 40.28 1.82
SD108 M ↓ 38.66 1.25 40.92 1.62
G 28 SD30 F ↓ 39.51 1.49 41.02 2.27
SD45 M ↓ 40.46 1.65 43.28 0.79
F ↓ 38.42 2.06 42.12 1.47
Plateletsi D 14 SD3 F ↓ 303 104.75 425 128.03
9, 14 SD86 M ↓ 232 17.16 354 67
F ↓ 172 46.64 356 101.49
E 18 SD3 M ↓ 224.67 154.19 394 95.96
F ↓ 201.3 89.58 480.8 123.48
22 M ↓ 261.67 138.01 394 95.96
F ↓ 272.56 114.52 480.8 123.48
F 25, 21 SD90 M ↑ 991.8 138.03 473.9 66.57
F ↑ 1037.6 164.13 495.22 127.88
G 27 SD45 F ↓ 618.7 149.08 809.9 155.31
Mean D 14 SD3 M ↑ 8 1.29 6.2 1.66
Platelet E 18 M ↑ 8.36 2.38 6.08 0.18
Volumej F ↑ 8.49 2.77 6.46 0.46
22 M ↑ 7.17 0.9 6.08 0.18
F ↑ 7.36 0.92 6.46 0.46
18 SD24 M ↑ 6.75 1.45 5.74 0.3
22 M ↑ 6.32 0.36 5.74 0.3
F 25, 21 SD90 M ↑ 6.76 0.46 6.38 0.52
COAGULATION
Activated D 14 SD24 F ↑ 83.71 7.65 73.35 10.95
Partial 9, 14 SD86 F ↑ 86.66 9.41 75 11.97
Thromboplastin E 18 SD3 M ↑ 105.96 27.18 54.02 10.85
Timek F ↑ 119.27 15.85 85.93 19.77
22 M ↑ 114.06 17.65 54.02 10.85
F ↑ 117.5 6.52 85.93 19.77
18 SD24 F ↑ 107.19 12.35 84.32 14.21
SD45 M ↑ 108.11 7.65 81.11 14.94
F ↑ 104.88 19.47 85.15 15.44
22 M ↑ 105.47 14.17 81.11 14.94
F ↑ 103.81 8.87 85.15 15.44
F 25, 21 SD90 M ↑ 135.1 17.4 86.51 8.13
F ↑ 132.5 15.83 93.69 17.85
SD108 M ↑ 100.72 10.29 81.76 9.18
G 27 Pre-dose F ↓ 79.02 10.35 87.37 6.76
SD30 F ↑ 112.9 15.21 96.93 16.31
SD45 M ↑ 117.6 12.58 96.48 8.1
Prothrombin D 14 SD3 M ↓ 8.69 0.8 8.93 0.9
Timel F ↓ 8.64 0.8 8.93 0.7
SD24 M ↓ 8.96 0.12 9.17 0.12
F ↓ 9.02 0.1 9.27 0.14
E 18 SD3 M ↓ 5.88 0.03 6.17 0.09
F ↓ 5.88 0.06 6.23 0.11
22 SD3 M ↓ 5.87 0.05 6.17 0.09
F ↓ 5.9 0.06 6.23 0.11
18 SD24 M ↓ 6.02 0.09 6.5 0.12
F ↓ 6.02 0.09 6.57 0.24
22 M ↓ 6.05 0.12 6.5 0.12
F ↓ 6.05 0.14 6.57 0.24
18 SD45 M ↓ 6.27 0.14 6.56 0.12
F ↓ 6.26 0.16 6.62 0.25
22 M ↓ 6.3 0.12 6.56 0.12
F ↓ 6.33 0.09 6.62 0.25
F 25, 21 SD90 F ↓ 6.74 0.18 6.98 0.18
SD108 M ↓ 6.57 0.07 6.99 0.08
F ↓ 6.54 0.08 7.05 0.21
G 27 SD57 F ↓ 6.45 0.11 6.99 0.17
Fibrinogenm F 25, 21 SD90 M ↑ 725.7 84.62 335.1 70.08
F ↑ 653.2 81.96 273 65.69
SD108 M ↑ 665.8 78.7 347.8 28.53
F ↑ 559.6 77.32 262.5 40.9
G 27 SD4 M ↑ 472 77.46 361.6 29.47
F ↑ 359.1 47.83 294.1 48.54
SD30 M ↑ 407.3 95.76 307.5 49.2
F ↑ 353.8 144.62 247 21.58
SD45 M ↑ 620.8 41.91 339.8 50.42
F ↑ 569.6 91.1 269.8 17.92
SD57 F ↑ 297.8 42.58 238 14.92
a

Gender-matched concurrent controls

b

S.D. = standard deviation.

c

Cholesterol male reference range 50–131, female reference range. 51–137.

d

Triglycerides male reference range 35–274, female reference range 34–150.

e

Globulin male reference range 1.2–2.6, female reference range 1.5–2.6.

f

A/G ratio male reference range 1.4–2.9, female reference range 1.4–2.6.

g

Hemoglobin male reference range 11.3–15, female reference range 11.1–14.5.

h

Hematocrit male reference range 33.4–45.5, female reference range 33.3–43.8.

i

Platelets male reference range 237–725, female reference range 258–712.

j

MPV male reference range 5.5–7.6, female reference range 5.5–7.9.

k

APTT male reference range 51.56–113, female reference range 50.2–112.

l

PT male reference range 6–8.67, female reference range 6–8.63.

m

This parameter (fibrinogen) was only measured in Studies F (Marburg) & G (Ad35), so the absence of values from Studies D (Ad5 HIV) & E (Ebola) in this table should not be construed as there being no differences, but rather no measurements; male reference range: 224–500, female reference range 198–447

Cells highlighted in light gray represent mean values that fall outside the historical reference range.